$8.60
+0.13 (+1.53%)
Open$8.50
Previous Close$8.47
Day High$8.75
Day Low$8.30
52W High$10.14
52W Low$4.50
Volume—
Avg Volume121.1K
Market Cap180.97M
P/E Ratio—
EPS$-1.09
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+281.0% upside
Current
$8.60
$8.60
Target
$32.77
$32.77
$27.05
$32.77 avg
$46.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.35M | 16.36M | 16.49M |
| Net Income | -24,979,548 | -919,800 | -1,097,385 |
| Profit Margin | -202.2% | -5.6% | -6.7% |
| EBITDA | -27,359,773 | -1,433,447 | -1,263,705 |
| Free Cash Flow | — | -1,064,720 | -1,173,966 |
| Rev Growth | — | +3.8% | -10.0% |
| Debt/Equity | — | 1.22 | 1.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |